YMRC
IRMD icon

Yorktown Management & Research Company’s iRadimed IRMD Stock Holding History

Yorktown Management & Research Company’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,250
Closed -$217K – 267
2026
Q1 		$217K Hold
2,250
– – 0.18% 206
2025
Q4 		$219K Buy
+2,250
New +$193K 0.18% 210

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
SI
Shaker Investments Cleveland, Ohio $278M AUM 69.83% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Yorktown Management & Research Company's IRMD Position: Q2 2026 in Review

Yorktown Management & Research Company sold out of iRadimed (IRMD) in Q2 2026, closing a stake of 2,250 shares — an estimated $217K sold.

Yorktown Management & Research Company first reported a position in IRMD in Q4 2025 and held it in 2 quarters. The position peaked at $219K in Q4 2025. 87 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Yorktown Management & Research Company reported no remaining iRadimed position as of Q2 2026 after selling out during the quarter.
  • Yorktown Management & Research Company sold 2,250 iRadimed shares in Q2 2026, an estimated $217K.
  • Yorktown Management & Research Company first reported a position in iRadimed in Q4 2025 and held it in 2 quarters.
  • Yorktown Management & Research Company's iRadimed position peaked at $219K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.